Search

Erythropoietin

Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label].

N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID

Hyaluronic acid

HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. … [A230133] Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms.

5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine

5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine

TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATE

Somatotropin

[A228188] Recombinant HGH has been commercially available since 1985 after its development by Genentech. … [Somatrem] was the first available recombinant HGH and was largely replaced by somatropin, another form of recombinant HGH.

Benzalkonium

Benzalkonium is a quaternary ammonium compound used as a biocide, a cationic surfactant, and as a phase transfer agent [FDA Label]. Benzalkonium is more commonly contained in consumer products in its salt form, benzalkonium chloride [FDA...

Esomeprazole

As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists … Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme

5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine